PATENT CLAIM ANALYSIS

Application Number: 15934526
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["530", "387100"]

Abstract:
This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.

Claim (Index 25):
The method of  claim 14 , wherein the light chain of said antibody comprises SEQ ID NO: 87 and the heavy chain of said antibody comprises SEQ ID NO: 77.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 90.0
- Lexical Diversity: 1.375
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14655982', '12751791', '15510545', '14460871', '11715307']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7303734076985388
- 35 USC 102 Novelty (BERT): 0.6001008533921656
- Combined Prediction Score: 0.7173461522679014
- Mean Citation Score: 431.43559000000016
- Max Citation Score: 566.4305
- Similarity Product: 456.2721418873668

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test